Type I Hypersensitivity is an indication for drug development with over 200 pipeline drugs currently active. According to GlobalData, preregistered drugs for Type I Hypersensitivity have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Type I Hypersensitivity compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Type I Hypersensitivity overview
Type 1 hypersensitivity is a type of allergic reaction that occurs when an individual is exposed to a specific antigen, called an allergen, for the second or subsequent time. This reaction is mediated by immunoglobulin E (IgE) antibodies, which bind to mast cells and basophils in the tissues and blood. When the allergen cross-links the IgE antibodies on these cells, they release various inflammatory mediators, such as histamine, leukotrienes, and prostaglandins, that cause vasodilation, smooth muscle contraction, and increased vascular permeability. The symptoms of type 1 hypersensitivity can range from mild (such as sneezing, itching, and hives) to severe (such as bronchoconstriction, hypotension, and anaphylactic shock). The most common allergens that trigger type 1 hypersensitivity are proteins from plants, animals, insects, foods, drugs, and vaccines. The diagnosis of type 1 hypersensitivity is based on clinical history, skin tests, and measurement of serum IgE levels. The treatment of type 1 hypersensitivity includes avoidance of the allergen, administration of antihistamines, corticosteroids, epinephrine, and immunotherapy.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Type I Hypersensitivity, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
